ArticleFrontiers in oncology2026
PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: To investigate the clinical efficacy and potential mechanisms of immune checkpoint inhibitors (PD-1 inhibitors) combined with chemotherapy and targeted therapy in ovarian cancer patients with brain metastases, and to analyze the relationship between the number of brain metastases, tumor microenvironment characteristics, and prognosis. Materials and methods: A retrospective analysis was conducted on the clinical data of two ovarian cancer patients with brain metastases. One patient had a single brain metastasis and received comprehensive treatment including surgery, radiotherapy, chemotherapy, PD-1 inhibitor (tislelizumab), and PARP inhibitor (niraparib). The other patient had multiple brain metastases and was treated with chemotherapy combined with PD-1 inhibitor. Tissue microarray immunohistochemistry was used to detect the expression of immune markers (CD4, CD8, CD31, PD-L1, etc.) in primary tumors and brain metastases. Gene testing was performed to evaluate homologous recombination repair deficiency (HRD) status. Results: The patient with a single brain metastasis achieved complete response (CR) after comprehensive treatment, with significantly prolonged progression-free survival. The patient with multiple brain metastases showed significant short-term efficacy but died due to complications. Immunohistochemistry revealed higher expression of CD4, CD8, CD31, and PD-L1 in brain metastases compared to the primary tumor, suggesting increased T-cell infiltration and enhanced immune activity in the tumor microenvironment. Gene testing confirmed HRD positivity in the first patient, and maintenance therapy with PARP inhibitor combined with PD-1 inhibitor was effective. Conclusion: PD-1 inhibitors combined with chemotherapy and targeted therapy may provide a new treatment option for ovarian cancer patients with brain metastases, particularly those with single brain metastases who can achieve long-term survival through comprehensive treatment. The immune microenvironment characteristics of brain metastases (e.g., high PD-L1 expression, T-cell infiltration) may predict the efficacy of immunotherapy, but the prognosis for patients with multiple brain metastases remains poor. Further research is needed to explore the correlation between peripheral blood immune markers and treatment response in brain metastases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.